All In Biotech

Drug Trial Radar · NCT07452510

Comparison of Dry Needling and Two Botulinum Toxins for Bruxism

Evaluation of the Effects of Dry Needling and Botulinum Toxin Applications on VAS Scores and Muscle Thickness in the Masseter and Temporalis Muscles of Patients Diagnosed With Bruxism

Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

Jan 9, 2026

Primary completion

Apr 8, 2026

Study completion Apr 8, 2026

Sponsor

Lead sponsor
Recep Tayyip Erdogan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Aim: The aim of this study is to prospectively compare the clinical efficacy of Dry Needling (DN), Nabota (PrabotulinumtoxinA), and Dysport (AbobotulinumtoxinA) treatments on the thickness of masseter and anterior temporal muscles and pain intensity (VAS) in patients diagnosed with chronic bruxism. 2. Material and Method: This randomized, prospective, and single-blind clinical study will be conducted on 60 patients diagnosed with bruxism. Patients will be divided into three groups: Dry Needling (n=20), Nabota (n=20), and Dysport (n=20). Pain levels will be assessed using the Visual Analog Scale (VAS) at baseline, 1st month, and 3rd month. Muscle thicknesses will be measured using ultrasonography (USG) at baseline and 3rd month. Data distribution will be analyzed using the Kolmogorov-Smirnov test; intergroup comparisons will be performed using ANOVA and Post-hoc Duncan tests. 3. Results:The results will be analyzed following the completion of the 3-month follow-up period

Conditions

  • Bruxism
  • Sleep Bruxism, Adult
  • Awake Bruxism
  • Masseter Muscle Hypertrophy
  • Temporomandibular Disorders

Interventions

  • Dry Needling (DN)Procedure

    Deep dry needling application to the masseter and anterior temporal muscles. The procedure was performed in 3 sessions with one-week intervals.

  • PrabotulinumtoxinADrug

    Injection of PrabotulinumtoxinA. A total of 50 Units was administered: 15 Units per masseter muscle and 10 Units per anterior temporal muscle, injected bilaterally in a single session.

  • AbobotulinumtoxinaDrug

    Injection of AbobotulinumtoxinA. A total of 500 Units (reconstituted to approximately 167 Units for equivalence) was administered: 50 Units per masseter muscle and 33.3 Units per anterior temporal muscle, injected bilaterally in a single session.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Intensity Measured by Visual Analog Scale (VAS)Time frame: Baseline, 1 month, and 3 months.
  2. Masseter and Anterior Temporal Muscle Thickness Via Ultrasonography (USG)Time frame: 3rd month post-treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Recep Tayyip Erdogan university

    Rize, Center, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.